Bill > H0657

This bill creates new regulations for drug pricing within the Medicaid program, focusing on the 340B Drug Pricing Program (a federal program that allows certain healthcare providers to purchase outpatient drugs at discounted prices). The legislation requires drug manufacturers to sell specified drugs to Medicaid pharmacies at 340B discounted prices, particularly for drugs on the Medicaid preferred drug list. If manufacturers sell these drugs at a price higher than the state's negotiated price, they must pay a rebate to the state. Pharmacy benefits managers must pay Medicaid pharmacies the 340B discounted price plus a professional dispensing fee for eligible drugs. Drug wholesalers and distributors are also mandated to sell drugs at the 340B discounted price and are prohibited from modifying existing pricing models to exclude these drugs. The bill limits the use of 340B discounted drugs to Medicaid recipients only, ensuring the pricing benefits are directed specifically to the Medicaid population. The provisions will take effect on January 1, 2026, giving stakeholders time to prepare for the new pricing requirements.

Health and Social Services

https://www.flsenate.gov/Session/Bill/2025/657